Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Sezary Syndrome 2Recurrence 2Neoplasms 2Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Soft Tissue Neoplasms 1Sarcoma 1Respiratory Distress Syndrome 1Radiation Pneumonitis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1

Interventions

Mycophenolic Acid 7fludarabine phosphate 6Radiotherapy 6Cyclophosphamide 6Antilymphocyte Serum 6Rituximab 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Cyclosporine 5Whole-Body Irradiation 4Tacrolimus 4Flow Cytometry 4Etoposide 4Cord Blood Stem Cell Transplantation 4Busulfan 4tanespimycin 3Methotrexate 3Melphalan 3Lenalidomide 3Bortezomib 3plerixafor 2nelarabine 2mogamulizumab 2aldesleukin 2Vincristine 2Polymerase Chain Reaction 2Photopheresis 2Moxifloxacin 2Magnetic Resonance Spectroscopy 2Immunosuppression Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Sezary Syndrome × Disulfides × Clear all
NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

National Cancer Institute (NCI)

Phase 1/2 Terminated
8 enrolled 8 charts
Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT04676087 2024-08-13

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Emory University

Phase 1/2 Terminated
5 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡